Recommencement of atezolizumab with associated pulmonary sarcoid-like reaction.

IF 0.8 Q4 RESPIRATORY SYSTEM

Respirology Case Reports Pub Date : 2024-04-26 eCollection Date: 2024-05-01 DOI:10.1002/rcr2.1363

Khai Tam, Michael Wallace, Siobhain Mulrennan

引用次数: 0

Abstract

An 81 year old male with Child-Pugh A cirrhosis and metastatic hepatocellular carcinoma (HCC) treated with 3-weekly atezolizumab and bevacizumab developed a pulmonary sarcoid-like reaction (SLR) after 5 months. Atezolizumab, an immune checkpoint inhibitor, was identified as the likely culprit. He was treated with prednisolone, resulting in improvement, and was successfully rechallenged with both atezolizumab and bevacizumab.

查看原文本刊更多论文

重新开始使用阿特珠单抗并伴有肺肉样瘤样反应。

一名 81 岁男性患者患有 Child-Pugh A 型肝硬化和转移性肝细胞癌（HCC），接受了每周 3 次的阿特珠单抗和贝伐珠单抗治疗，5 个月后出现了肺肉样瘤样反应（SLR）。免疫检查点抑制剂阿特珠单抗可能是罪魁祸首。他接受了泼尼松龙治疗，病情有所好转，并成功地再次接受了阿特珠单抗和贝伐珠单抗治疗。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Respirology Case Reports RESPIRATORY SYSTEM-

CiteScore

1.40

自引率

0.00%

发文量

178

审稿时长

8 weeks

期刊介绍： Respirology Case Reports is an open-access online journal dedicated to the publication of original clinical case reports, case series, clinical images and clinical videos in all fields of respiratory medicine. The Journal encourages the international exchange between clinicians and researchers of experiences in diagnosing and treating uncommon diseases or diseases with unusual presentations. All manuscripts are peer-reviewed through a streamlined process that aims at providing a rapid turnaround time from submission to publication.